A5046639150- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
- Sarcoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Gastrointestinal disorders and treatments
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Vascular Tumors and Angiosarcomas
- Genetic factors in colorectal cancer
- Metastasis and carcinoma case studies
- Cardiac tumors and thrombi
- Neurofibromatosis and Schwannoma Cases
- Fibroblast Growth Factor Research
- PI3K/AKT/mTOR signaling in cancer
- Medical Imaging and Pathology Studies
- Monoclonal and Polyclonal Antibodies Research
- Pancreatic and Hepatic Oncology Research
- Cancer therapeutics and mechanisms
- Lung Cancer Diagnosis and Treatment
- Epigenetics and DNA Methylation
Universitätsmedizin Göttingen
2015-2025
Essen University Hospital
2019-2024
Deutschen Konsortium für Translationale Krebsforschung
2020-2024
Institut für Hämatopathologie Hamburg
2024
University of Duisburg-Essen
2019-2024
Hesse (Germany)
2023-2024
Biomarker Technologies (China)
2024
Sunny BioDiscovery (United States)
2023
Bayer (France)
2023
Endocyte (United States)
2023
The pattern of mutations in human lung cancer differs by tumor subtype and is a useful addition to histology for selecting targeted therapy improving patient survival.
Abstract Gastrointestinal stromal tumors (GIST) are characterized by a strong KIT receptor activation most often resulting from mutations. In smaller subgroup of without mutations, analogous activating mutations found in the platelet-derived growth factor α (PDGFRα) gene. Both PDGFRα and receptors targets tyrosine kinase inhibitor imatinib (Glivec) which has improved treatment advanced GISTs significantly. However, show secondary progress under therapy with after initial response. One...
To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy either AZD9291 or rociletinib (CO-1686).
The approval of vemurafenib in the US 2011 and Europe 2012 improved therapy not resectable or metastatic melanoma. Patients carrying a substitution valine to glutamic acid at codon 600 (p.V600E) leucine (p.V600K) BRAF show complete partial response. Therefore, precise identification underlying somatic mutations is essential. Herein, we evaluate sensitivity, specificity feasibility six different methods for detection mutations. Samples harboring p.V600E as well rare exon 15 were compared...
Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer (NSCLC) patients with and their sensitivity to classical epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) is highly heterogeneous. Patients harboring one group uncommon, recurrent (G719X, S768I, L861Q) respond EGFR-TKI. Exon 20 insertions are mostly insensitive EGFR-TKI but display exon inhibitors. Clinical outcome data very rare point compound upon systemic treatments still sparse date.In this...
Patients affected by neurofibromatosis type 1 (NF-1) have an increased risk of developing gastrointestinal stromal tumors (GIST). NF-1-associated GISTs are usually wild for c-KIT and platelet-derived growth factor receptor-alpha (PDGFR-alpha) mutations harbor a different oncogenic molecular mechanism. The lack data on imatinib activity raises the question whether to enroll these patients in clinical trials. We analyzed large series NF-1 related discuss therapeutic implications.Clinical,...
MET is a potential therapeutic target in lung cancer and both tyrosine kinase inhibitors monoclonal antibodies have entered clinical trials. signaling can be activated by various mechanisms, including gene amplification. In this study, we aimed to investigate amplification status adeno- squamous cell carcinomas of the lung. We propose clearly defined scores provide epidemiologic data on cancer.We evaluated prevalence increased copy numbers 693 treatment-naïve cancers FISH, clear cutoff...
Inflammatory fibroid polyps (IFPs) are mesenchymal tumours which arise in the submucosa and mucosa of gastrointestinal tract. To date, pathogenesis is unknown IFPs considered reactive non-neoplastic lesions. Investigating a series 23 IFPs, we made observation that consistently express PDGFRA. further elucidate pathogenetic role PDGFRA, performed mutational analyses exons 10, 12, 14, 18. As characterized by an inflammatory infiltrate rich eosinophils, used fluorescence situ hybridization...
Abstract Purpose: Although the mutational status in gastrointestinal stromal tumors (GIST) can predict response to treatment with tyrosine kinase inhibitors, role of tumor genotype as a prognostic factor remains controversial. The ConticaGIST study sought determine pathologic and molecular factors associated disease-free survival (DFS) patients operable, imatinib-naive GIST. Experimental Design: Clinicopathologic data from 1,056 localized GIST who underwent surgery curative intention (R0/R1)...
Residual tumor cells remain beyond the margins of every glioblastoma (GBM) resection. Their resistance to postsurgical therapy is considered a major driving force mortality, but their biology remains largely uncharacterized. In this study, residual were derived via experimental biopsy resection margin after standard neurosurgery for direct comparison with samples from routinely resected tissue. vitro analysis proliferation, invasion, stem cell qualities, GBM-typical antigens, genotypes, and...
The first evaluation of pelvic extended lymph node dissection (pLND) in oligometastatic prostate cancer (PCa) detected by (68)Ga-PSMA PET/CT.Retrospective analysis 35 PCa patients underwent PET/CT affected biochemical recurrence (BCR) after curative treatment (n = 23) or before primary therapy high-risk 12). We performed pLND associated with pathologic imaging 17 men nodal PCa.Indicative lesions for were 91.4% (32 35) patients. Nodal, bone, visceral (pulmonary), and within the suspected...
We recently reported fibroblast growth factor receptor-type 1 (FGFR1) amplification to be associated with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. This makes a novel target for directed therapy these tumors. To reproducibly identify patients clinical studies, we developed standardized reading and evaluation strategy fluorescence in-situ hybridization (FISH) propose criteria, describe different patterns of low- high-level amplifications report on the prevalence...
Fibroblast activation protein (FAP) is overexpressed in several solid tumors and therefore represents an attractive target for radiotheranostic applications. Recent investigations demonstrated rapid high uptake of small-molecule inhibitors FAP (68Ga-FAPI-46) PET imaging. Here, we report our initial experience the feasibility safety 90Y-FAPI-46 radioligand therapy extensively pretreated patients with tumors. Methods: Patients were considered if they showed both exhaustion all approved...
<b>Introduction:</b> Bone and soft tissue sarcomas express fibroblast activation protein (FAP) on tumor cells associated fibroblast. Therefore, FAP is a promising therapeutic diagnostic target. Novel radio-labelled FAP-Inhibitors (e.g. <sup>68</sup>Ga-FAPI46) have shown high uptake in positron emission tomography (PET) sarcoma patients. Here we report endpoints of the FAPI-PET prospective observational trial. <b>Methods:</b> Forty-seven patients with bone or undergoing clinical...
Performance of the new CE-IVD-marked HercepTest™ mAb pharmDx (Dako Omnis) assay (HercepTest (mAb)) was compared against PATHWAY® anti-HER-2/neu (4B5) (PATHWAY 4B5) using 119 pre-selected breast cancer samples covering entire range HER2 immunohistochemistry (IHC) expression scores (0, 1 + , 2 3 +). The sensitivity and specificity both assays were assessed based on consensus IHC amplification status, as determined by fluorescence in situ hybridization (FISH) according to 2018 ASCO/CAP testing...
Imatinib resistance in GI stromal tumors (GISTs) is primarily caused by secondary
(1) Colorectal cancer (CRC) is a leading cause of cancer-related deaths globally. Cancer-associated fibroblasts (CAFs) are major components CRC’s tumour microenvironment (TME), but their biological background and interplay with the TME remain poorly understood. This study investigates CAF biology its impact on CRC progression. (2) The cohort comprises 155 cases, including CRC, diverse localizations, adenomas, inflammations, controls. Digital gene expression analysis examines genes associated...
Aims and methods: Desmoid‐type fibromatosis (desmoid) is a fibroblastic tumour that shows locally aggressive growth. Mesenteric desmoid rare lesion shares morphological biological features with fibromatoses occurring in the abdominal wall or extraabdominal sites, but differs terms of gross appearance clinical presentation. We report on series 56 cases mesenteric desmoids from our consultation files compare them non‐mesenteric retroperitoneal fibrosis. Results: Primary diagnosis desmoid‐type...